Diabetic cardiomyopathy remains one of the most underappreciated cardiovascular complications, affecting tens of millions of people with diabetes who may have no overt coronary artery disease yet still face progressive cardiac decline. Understanding the molecular switches that drive this deterioration could open entirely new therapeutic avenues — and this work from Circulation Research identifies a compelling candidate hiding inside the mitochondria itself.
The STING protein (stimulator of interferon genes) has long been studied as an innate immune sentinel, triggering interferon responses when cytosolic DNA is detected. This study reveals a previously unexplored noncanonical role: STING relocates to mitochondrial membranes in the diabetic heart and directly reprograms cardiac metabolism. Using two distinct diabetic mouse models — the genetic db/db strain and a diet-plus-streptozotocin chemically induced model — the investigators combined single-cell RNA sequencing, Seahorse extracellular flux analysis, and 13C-glucose tracing metabolomics to map the metabolic consequences. A key mechanistic finding centers on ENO1 (enolase 1), a glycolytic enzyme whose activity is modulated by STING through posttranslational modifications including S-palmitoylation and S-sulfhydration. STING knockout mice showed measurable differences in glycolytic flux, lactate and pyruvate accumulation, and cardiac functional parameters compared to diabetic controls.
What makes this finding notable is the dual nature of STING's involvement — bridging innate immune signaling and mitochondrial metabolic control in the same tissue under diabetic stress. This intersection of immunometabolism and cardiac energy handling is an emerging frontier. The healthy heart derives roughly 70% of its ATP from fatty acid oxidation, but in diabetic cardiomyopathy this shifts toward glucose dependence with impaired efficiency — a metabolic inflexibility that STING may partly orchestrate. The limitation here is significant: all data are from mouse models, and whether mitochondrial STING behaves identically in human diabetic myocardium requires validation. Nonetheless, identifying S-palmitoylation and S-sulfhydration as regulatory modifications of STING adds mechanistic specificity that elevates this beyond typical observational work, making it an incremental but mechanistically rich advance.